WO2001058474A3 - Microencapsulation and sustained release of biologically active agent - Google Patents

Microencapsulation and sustained release of biologically active agent Download PDF

Info

Publication number
WO2001058474A3
WO2001058474A3 PCT/US2001/003160 US0103160W WO0158474A3 WO 2001058474 A3 WO2001058474 A3 WO 2001058474A3 US 0103160 W US0103160 W US 0103160W WO 0158474 A3 WO0158474 A3 WO 0158474A3
Authority
WO
WIPO (PCT)
Prior art keywords
biologically active
sustained release
polymer
stable
active acid
Prior art date
Application number
PCT/US2001/003160
Other languages
French (fr)
Other versions
WO2001058474A2 (en
Inventor
Mark A Tracy
Kevin L Ward
David S Scher
J Keith Johnson
Original Assignee
Alkermes Inc
Mark A Tracy
Kevin L Ward
David S Scher
J Keith Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc, Mark A Tracy, Kevin L Ward, David S Scher, J Keith Johnson filed Critical Alkermes Inc
Priority to AU33175/01A priority Critical patent/AU767632B2/en
Priority to CA002400186A priority patent/CA2400186A1/en
Priority to EP01905277A priority patent/EP1253936A2/en
Priority to JP2001557582A priority patent/JP2003522156A/en
Publication of WO2001058474A2 publication Critical patent/WO2001058474A2/en
Publication of WO2001058474A3 publication Critical patent/WO2001058474A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Abstract

This invention relates to sustained release compositions, and methods of forming and using said compositions, for the sustained release of biologically active acid-stable or free sulfhydryl-containing proteins, in particular β-IFN. The sustained release composition of this invention comprises a biocompatible polymer having dispersed therein a stabilized biologically active acid-stable or free sulfhydryl-containing protein formulation and a nonionic polymer surfactant. The method of the invention, for forming a composition for the sustained release of biologically active acid-stable or free sulfhydryl-containing protein, in particular β-IFN, includes dissolving a polymer in a polymer solvent to form a polymer solution, adding a stabilized biologically active acid-stable or free sulfhydryl-containing protein formulation and a nonionic surfactant to the polymer solution, and then solidifying the polymer to form a polymer matrix containing the stabilized biologically active acid-stable or free sulfhydryl-containing protein formulation, and a nonionic surfactant. The method of using the sustained release composition of the present invention comprises providing a therapeutically effective blood level of biologically active acid-stable or free sulfhydryl-containing protein in a subject for a sustained period by administering to the subject a dose of the sustained release composition described herein.
PCT/US2001/003160 2000-02-10 2001-01-31 Microencapsulation and sustained release of biologically active agent WO2001058474A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU33175/01A AU767632B2 (en) 2000-02-10 2001-01-31 Microencapsulation and sustained release of biologically active agent
CA002400186A CA2400186A1 (en) 2000-02-10 2001-01-31 Microencapsulation and sustained release of biologically active agent
EP01905277A EP1253936A2 (en) 2000-02-10 2001-01-31 Microencapsulation and sustained release of biologically active agent
JP2001557582A JP2003522156A (en) 2000-02-10 2001-01-31 Microencapsulation and sustained release of biologically active drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/501,934 2000-02-10
US09/501,934 US6465425B1 (en) 2000-02-10 2000-02-10 Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins

Publications (2)

Publication Number Publication Date
WO2001058474A2 WO2001058474A2 (en) 2001-08-16
WO2001058474A3 true WO2001058474A3 (en) 2002-02-14

Family

ID=23995624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/003160 WO2001058474A2 (en) 2000-02-10 2001-01-31 Microencapsulation and sustained release of biologically active agent

Country Status (6)

Country Link
US (2) US6465425B1 (en)
EP (1) EP1253936A2 (en)
JP (1) JP2003522156A (en)
AU (1) AU767632B2 (en)
CA (1) CA2400186A1 (en)
WO (1) WO2001058474A2 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565888B1 (en) 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
PT1429731E (en) * 2001-09-19 2007-04-30 Elan Pharma Int Ltd Nanoparticulate insulin formulations
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
WO2004035762A2 (en) 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CN100353997C (en) 2003-02-28 2007-12-12 中外制药株式会社 Stabilized preparation containing protein
US20040197413A1 (en) * 2003-04-04 2004-10-07 Genteric, Inc. Spray dry coacervation systems and methods
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
ES2226567B1 (en) * 2003-06-20 2006-07-01 Universidad De Santiago De Compostela NANOPARTICULAS OF HIALURONIC ACID.
ES2232287B1 (en) * 2003-07-04 2006-11-01 Advanced In Vitro Cell Technologies, S.L. POLYOXYETHYLATE DERIVATIVES NANOPARTICLES.
EP2462923A3 (en) * 2003-07-18 2012-08-29 Oakwood Laboratories L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
DE10333317A1 (en) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulation for protein medicines without the addition of human serum albumin (HSA)
US7090433B2 (en) * 2003-10-07 2006-08-15 Steve Searby Underground cable laying apparatus
AU2005209199B2 (en) * 2004-01-16 2008-09-11 Biodel Inc. Sublingual drug delivery device
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
PL1734971T3 (en) * 2004-04-15 2012-08-31 Alkermes Pharma Ireland Ltd Polymer-based sustained release device
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US20060110423A1 (en) * 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
ES2246694B1 (en) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. PEGILATED NANOPARTICLES.
ES2246695B1 (en) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. STIMULATING COMPOSITION OF THE IMMUNE RESPONSE THAT INCLUDES NANOPARTICLES BASED ON A COPYLIMER OF METHYL VINYL ETER AND MALEIC ANHYDRIDE.
US7879320B2 (en) * 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations
EP1750751B1 (en) 2004-06-01 2013-04-10 Ares Trading S.A. Stabilized interferon liquid formulations
CN1984674A (en) * 2004-06-07 2007-06-20 纳斯泰克制药公司 Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides
EP1778278B1 (en) * 2004-07-16 2014-05-21 Oakwood Laboratories L.L.C. Gonadotropin releasing hormone antagonists
US20060104969A1 (en) * 2004-08-16 2006-05-18 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
WO2006078841A1 (en) * 2005-01-21 2006-07-27 President And Fellows Of Harvard College Systems and methods for forming fluidic droplets encapsulated in particles such as colloidal particles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
TW200640492A (en) * 2005-02-21 2006-12-01 Lg Life Sciences Ltd Sustained release composition of protein drug
US20070042041A1 (en) * 2005-08-17 2007-02-22 Board Of Trustees Of The University Of Arkansas Drug-surfactant complexes for sustained release
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
NZ570668A (en) * 2006-02-01 2010-07-30 Samyang Corp Composition for inhibiting adhesion
AU2007238114B2 (en) 2006-04-12 2010-10-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
MX2008014870A (en) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator.
CN102274557B (en) 2006-08-09 2014-12-03 精达制药公司 Osmotic delivery systems and piston assemblies
WO2008118712A1 (en) * 2007-03-22 2008-10-02 Alkermes, Inc. Coacervation process
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
JP2010534681A (en) * 2007-07-25 2010-11-11 バイオレックス・セラピューティクス インコーポレイテッド Controlled release interferon preparation and treatment of HCV infection using the same
US20090105368A1 (en) * 2007-10-19 2009-04-23 Bisco, Inc. Time-controlled intraoral film former system for intraoral use
WO2009080699A2 (en) 2007-12-20 2009-07-02 Merck Serono S.A. Peg-interferon-beta formulations
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US20100189800A1 (en) * 2009-01-23 2010-07-29 Peter Markland Continous double emulsion process for making microparticles
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CA2775676C (en) 2009-09-28 2016-08-16 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
EP2308478A1 (en) * 2009-10-06 2011-04-13 Abbott GmbH & Co. KG Delivery system for sustained release of a calcium-channel blocking agent
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR102276161B1 (en) 2011-10-25 2021-07-14 프로테나 바이오사이언시즈 리미티드 Antibody formulations and methods
US20130302366A1 (en) 2012-05-09 2013-11-14 Christopher Marshall Conformationally Specific Viral Immunogens
US10125172B2 (en) 2013-07-25 2018-11-13 Calder Biosciences Inc. Conformationally stabilized RSV pre-fusion F proteins
ES2832733T3 (en) 2013-08-03 2021-06-11 Calder Biosciences Inc Methods of preparation and use of influenza virus hemagglutinin complexes
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (en) 2015-06-03 2021-11-05 因塔西亚制药公司 Implant placement and removal system
EP3370694A1 (en) * 2015-11-06 2018-09-12 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Composition comprising a biocompatible and biodegradable polymer, nanocarries and a drug and methods of making and using the same
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (en) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Methods Including Continuous Administration of GLP-1 Receptor Agonists and Co-administration of Drugs
WO2020194034A1 (en) 2019-03-27 2020-10-01 Universidad De Chile Nanoparticle of chitosan and cyclodextrin containing encapsulated interferon and pharmaceutical compositions that contain it
WO2023154902A1 (en) * 2022-02-11 2023-08-17 Sameer Sabir Compositions of and methods for a cold slurry having hyaluronic acid

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251476A1 (en) * 1986-05-23 1988-01-07 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
FR2620621A1 (en) * 1987-09-21 1989-03-24 Bpd Biopharm Dev Ltd PHARMACEUTICAL COMPOSITION FOR SUSTAINED AND CONTROLLED DELIVERY OF WATER-INSOLUBLE POLYPEPTIDES
WO1991012882A1 (en) * 1990-02-22 1991-09-05 Medgenix Group S.A. Microspheres for the controlled release of water-soluble substances and process for preparing them
WO1996003116A1 (en) * 1994-07-25 1996-02-08 Alkermes Controlled Therapeutics, Inc. Controlled release of metal cation-stabilized interferon
WO1996028143A1 (en) * 1995-03-10 1996-09-19 Boehringer Mannheim Gmbh Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and method for the preparation thereof
WO1998027963A2 (en) * 1996-12-20 1998-07-02 Alza Corporation Gel composition and methods
WO1999024061A1 (en) * 1997-11-07 1999-05-20 Chiron Corporation Method for producing igf-1 sustained-release formulations

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252791A (en) 1979-10-19 1981-02-24 The Medical College Of Wisconsin, Inc. Interferon stabilization
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5643566A (en) 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4462940A (en) 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
EP0123291A2 (en) 1983-04-20 1984-10-31 Kyowa Hakko Kogyo Co., Ltd. Method for stabilizing interferon
JPS60100516A (en) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US4853218A (en) 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
US4871538A (en) 1987-07-13 1989-10-03 Schering Corporation Insoluble copper-alpha interferon complex
EP0307097B1 (en) 1987-09-08 1993-06-09 Takeda Chemical Industries, Ltd. Water-insolubilized cytokines
US5004605A (en) 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
JP2670680B2 (en) 1988-02-24 1997-10-29 株式会社ビーエムジー Polylactic acid microspheres containing physiologically active substance and method for producing the same
US4990336A (en) 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
DE69005800T2 (en) 1989-05-01 1994-05-19 Alkermes Inc METHOD FOR PRODUCING SMALL PARTICLES OF BIOLOGICALLY ACTIVE MOLECULES.
US5126147A (en) 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
MY107450A (en) 1990-06-04 1995-12-30 Schering Corp Method for preparing interferon alpha-2 crystals.
EP0533799B1 (en) 1990-06-20 1995-10-18 Advanced Polymer Systems, Inc. Compositions and methods for the controlled release of soluble active substances
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
US5176907A (en) 1991-08-13 1993-01-05 The Johns Hopkins University School Of Medicine Biocompatible and biodegradable poly (phosphoester-urethanes)
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
CA2143044C (en) 1994-02-21 2005-04-12 Yasutaka Igari Matrix for sustained-release preparation
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
AU705968B2 (en) 1995-06-07 1999-06-03 Alkermes Controlled Therapeutics, Inc. Device for releasing aggregation-stabilized, biologically active agent
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251476A1 (en) * 1986-05-23 1988-01-07 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
FR2620621A1 (en) * 1987-09-21 1989-03-24 Bpd Biopharm Dev Ltd PHARMACEUTICAL COMPOSITION FOR SUSTAINED AND CONTROLLED DELIVERY OF WATER-INSOLUBLE POLYPEPTIDES
WO1991012882A1 (en) * 1990-02-22 1991-09-05 Medgenix Group S.A. Microspheres for the controlled release of water-soluble substances and process for preparing them
WO1996003116A1 (en) * 1994-07-25 1996-02-08 Alkermes Controlled Therapeutics, Inc. Controlled release of metal cation-stabilized interferon
WO1996028143A1 (en) * 1995-03-10 1996-09-19 Boehringer Mannheim Gmbh Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and method for the preparation thereof
WO1998027963A2 (en) * 1996-12-20 1998-07-02 Alza Corporation Gel composition and methods
WO1999024061A1 (en) * 1997-11-07 1999-05-20 Chiron Corporation Method for producing igf-1 sustained-release formulations

Also Published As

Publication number Publication date
EP1253936A2 (en) 2002-11-06
AU3317501A (en) 2001-08-20
US20030138491A1 (en) 2003-07-24
CA2400186A1 (en) 2001-08-16
AU767632B2 (en) 2003-11-20
WO2001058474A2 (en) 2001-08-16
JP2003522156A (en) 2003-07-22
US6465425B1 (en) 2002-10-15

Similar Documents

Publication Publication Date Title
WO2001058474A3 (en) Microencapsulation and sustained release of biologically active agent
BR0008590A (en) Polymeric delivery agent, composition, unit dosage form, method for administering a biologically active agent to an animal requiring the agent, method for preparing a composition; it's composed
WO2005007185A3 (en) Formulation for a protein pharmaceutical without added human serum albumin (hsa)
CA2474698A1 (en) Polymer-based compositions for sustained release
CA2293797A1 (en) Aqueous carrier systems for water-insoluble materials
ATE537812T1 (en) COMPOSITIONS AND METHODS FOR IMPROVED ADMINISTRATION OF HYDROPHOBIC THERAPEUTIC ACTIVE INGREDIENTS
DE69614685T2 (en) AGENT FOR DELAYED RELEASE OF HUMAN GROWTH HORMONE
AU3694901A (en) A parasiticidal formulation and a method of making this formulation
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
NO20025621D0 (en) Sustained release pharmaceutical composition for parenteral administration of hydrophilic compounds
RS20070511A (en) Modified release pharmaceutical compositions and processes thereof
DE69520768T2 (en) Pharmaceutical preparations containing fluoxetine
WO2002074247A8 (en) Pharmaceutical formulations for sustained release
EE200100660A (en) Formulation for acid-labile active substances, unit active ingredient, method of preparation and microsphere
DE60019120D1 (en) FENOFIBRATE-CONTAINING PHARMACEUTICAL COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF
MY151470A (en) Controlled release solid preparation
HK1068282A1 (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for usein treatment of ulcerative colitis and crohn's di sease
DE69819145D1 (en) BIO-DEGRADABLE MICROPARTICLES WITH DELAYED ACTIVE SUBSTANCE RELEASE
DE60211769D1 (en) A process for the preparation of drug granules, the drug granules and pharmaceutical compositions containing them
CA2452395A1 (en) Pharmaceutically stable hemostatic compositions
DK1009380T3 (en) Process for the preparation of pharmaceutical formulations
CO5170438A1 (en) PROCESS FOR THE PREPARATION OF A COMPRESSED BETAHISTINE CONTROLLED LIBERATION BY GRANULATION IN THE FOUNDED STATE AND COMPRESSED CONTROLLED RELEASE OF BETAHISTIN OBTAINED BY MEANS OF THIS PROCESS
WO2003028624A3 (en) Levothyroxine compositions and methods
CA2395438A1 (en) Dry compositions containing hydrophobic amino acid
DE60200317D1 (en) Formulation with controlled release of active ingredient containing bupropion-HCI as the active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001905277

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 33175/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2400186

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 557582

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001905277

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 33175/01

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2001905277

Country of ref document: EP